Previous Close | 10.81 |
Open | 10.80 |
Bid | 11.05 x 800 |
Ask | 11.05 x 900 |
Day's Range | 10.45 - 10.90 |
52 Week Range | 6.01 - 13.14 |
Volume | |
Avg. Volume | 565,993 |
Market Cap | 755.785M |
Beta (5Y Monthly) | 1.15 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.72 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.63 |
Subscribe to Yahoo Finance Plus to view Fair Value for ZYME
Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of rolling biologics license application (BLA) filing with the FDA for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (US) with anticipated completion of regulatory submission in 1H 2024 by our partner, Jazz PharmaceuticalsInitiation of Phase 3 confirmatory tri
Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product candidatesStrong preclinical activity across multiple FRα-expressing indications for ZW191, a FRα-targeting antibody-drug conjugateNext generation trispecific T cell engager platforms with integrated CD28 costimulation demonstrate durable anti-tumor activity VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZY
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference: Zymeworks’ management will participate in one-on-one meetings and present on March 6th a